Author:
Chen Yingsha,Lin Yushi,Lu Huidan,Wu Xiaocui,Pan Ying,Xia Anyue,Pang Lantian,Ye Wenjing,Xu Feng
Reference22 articles.
1. Administration UFaD. Fact sheet for healthcare providers: emergency use authorization for paxlovid. https://www.fda.gov/media/155050/download. Published 2021. Accessed 12.
2. Administration UFaD. Fact sheet for healthcare providers: emergency use authorization for Lagevriotm (molnupiravir) capsules. https://www.fda.gov/media/155054/download Published 2021. Updated 12/23. Accessed.
3. Real-world effectiveness of Yindan Jiedu granules-based treatment on patients infected with the SARS-CoV-2 Omicron variants BA.2 combined with high-risk factors: A cohort study;Feng;Front Pharmacol,2022
4. Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management;Heskin;Lancet,2022
5. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial;Butler;Lancet,2023